Market data provided for informational purposes only. Not financial advice. Read disclaimers.
Market data provided for informational purposes only. Not financial advice. Read disclaimers.
Merck is a global pharmaceutical company known for Keytruda, the world's best-selling drug and the leading cancer immunotherapy (anti-PD-1). Keytruda generates over $25B in annual revenue and is approved across 30+ cancer types. Merck also operates an Animal Health division (the largest veterinary pharma business globally) and has a growing vaccine portfolio including Gardasil (HPV).
The Keytruda patent cliff (expected late 2028) is the dominant investment question. Merck's pipeline must replace $25B+ in Keytruda revenue — acquisitions, line extensions (subcutaneous Keytruda), and new oncology/immunology drugs are the critical watch items.